Home › Wilms Tumor › California › Mountain View
Wilms Tumor clinical trials in Mountain View, CA
4 studies for Wilms Tumor are looking for participants at sites in and around Mountain View (within about 30 miles). Open a study to see who can join and how to contact the study team.
Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
RecruitingPhase 2
- Lucile Packard Children's Hospital Stanford University, Palo Alto · 5 mi away
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
RecruitingPhase 2
- Lucile Packard Children's Hospital Stanford University, Palo Alto · 5 mi away
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
RecruitingPhase 1/2
- Lucille Packard Children's Hospital Stanford, Palo Alto · 5 mi away
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
RecruitingPhase 2
- Stanford Medicine Children's Health (Data Collection Only), Palo Alto · 5 mi away
About Wilms Tumor
Wilms' Tumor (or Nephroblastoma) is a rare type of cancer that affects one or both kidneys. Find a list of symptoms and treatments associated
More about Wilms Tumor on MedlinePlus
Wilms Tumor trials in other cities
- Washington, DC7 studies
- Memphis, TN6 studies
- Atlanta, GA5 studies
- Chicago, IL4 studies
- Boston, MA4 studies
- Los Angeles, CA4 studies
- St. Louis, MO4 studies
- New York City, NY4 studies
- Cincinnati, OH4 studies
- Houston, TX4 studies
- Aurora, CO4 studies
- Minneapolis, MN4 studies
Other studies in Mountain View
- Cancer (all types)41 studies
- Metastatic Cancer25 studies
- Breast Cancer24 studies
- Non-Small Cell Lung Cancer22 studies
- Acute Myeloid Leukemia19 studies
- Ovarian Cancer19 studies
- Lung Cancer17 studies
- Autism Spectrum Disorder17 studies
- Prostate Cancer15 studies
- Heart Failure14 studies
- Colorectal Cancer14 studies
- Acute Lymphoblastic Leukemia13 studies
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.